[{"address1": "5858 Horton Street", "address2": "Suite 455", "city": "Emeryville", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 505 2680", "website": "https://www.4dmoleculartherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.", "fullTimeEmployees": 227, "companyOfficers": [{"maxAge": 1, "name": "Dr. John F. Milligan Ph.D.", "age": 63, "title": "Executive Chairman", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 150000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David H. Kirn M.D.", "age": 61, "title": "Co-Founder, CEO & Director", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 1009003, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fariborz  Kamal Ph.D.", "age": 61, "title": "President & COO", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 734607, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Uneek  Mehra", "age": 51, "title": "Chief Financial & Business Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 823899, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Theresa  Janke", "age": 49, "title": "Co-Founder & Chief of Staff", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 652315, "exercisedValue": 0, "unexercisedValue": 703125}, {"maxAge": 1, "name": "Dr. Noriyuki  Kasahara M.D., Ph.D.", "age": 61, "title": "Chief Scientific Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 201288, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott P. Bizily J.D., Ph.D.", "age": 52, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert Y. Kim M.B.A., M.D.", "age": 63, "title": "Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 704843, "exercisedValue": 0, "unexercisedValue": 567555}, {"maxAge": 1, "name": "Dr. An  Song Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.", "age": 63, "title": "Senior VP & Therapeutic Area Head of Pulmonology", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 5, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.36, "open": 4.4, "dayLow": 4.17, "dayHigh": 4.4528, "regularMarketPreviousClose": 4.36, "regularMarketOpen": 4.4, "regularMarketDayLow": 4.17, "regularMarketDayHigh": 4.4528, "payoutRatio": 0.0, "beta": 2.83, "forwardPE": -1.2826747, "volume": 315903, "regularMarketVolume": 315903, "averageVolume": 443745, "averageVolume10days": 258280, "averageDailyVolume10Day": 258280, "bid": 4.17, "ask": 4.27, "bidSize": 1, "askSize": 1, "marketCap": 201975520, "fiftyTwoWeekLow": 2.235, "fiftyTwoWeekHigh": 19.689, "priceToSalesTrailing12Months": 8781.544, "fiftyDayAverage": 3.9207, "twoHundredDayAverage": 5.344725, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -125719576, "profitMargins": 0.0, "floatShares": 35394806, "sharesOutstanding": 46324600, "sharesShort": 4171819, "sharesShortPriorMonth": 4668859, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.090100005, "heldPercentInsiders": 0.0388, "heldPercentInstitutions": 0.95912004, "shortRatio": 8.76, "shortPercentOfFloat": 0.0938, "impliedSharesOutstanding": 47861500, "bookValue": 10.14, "priceToBook": 0.41617355, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -176439008, "trailingEps": -3.18, "forwardEps": -3.29, "enterpriseToRevenue": -5466.069, "enterpriseToEbitda": 0.632, "52WeekChange": -0.7529274, "SandP52WeekChange": 0.13161862, "quoteType": "EQUITY", "currentPrice": 4.22, "targetHighPrice": 45.0, "targetLowPrice": 10.0, "targetMeanPrice": 31.1, "targetMedianPrice": 33.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 321436992, "totalCashPerShare": 6.939, "ebitda": -198795008, "totalDebt": 23853000, "quickRatio": 11.95, "currentRatio": 12.364, "totalRevenue": 23000, "debtToEquity": 5.078, "revenuePerShare": 0.0, "returnOnAssets": -0.22185, "returnOnEquity": -0.32971, "grossProfits": -154104992, "freeCashflow": -90209752, "operatingCashflow": -153255008, "revenueGrowth": -0.5, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -3830.0715, "financialCurrency": "USD", "symbol": "FDMT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1752877013, "regularMarketTime": 1752868801, "postMarketChangePercent": -1.18483, "postMarketPrice": 4.17, "postMarketChange": -0.0499997, "regularMarketChange": -0.14, "regularMarketDayRange": "4.17 - 4.4528", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 443745, "fiftyTwoWeekLowChange": 1.9849999, "fiftyTwoWeekLowChangePercent": 0.8881432, "fiftyTwoWeekRange": "2.235 - 19.689", "fiftyTwoWeekHighChange": -15.469, "fiftyTwoWeekHighChangePercent": -0.7856671, "fiftyTwoWeekChangePercent": -75.29274, "earningsTimestamp": 1746734700, "earningsTimestampStart": 1754477940, "earningsTimestampEnd": 1754913600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.18, "epsForward": -3.29, "epsCurrentYear": -3.5603, "priceEpsCurrentYear": -1.1852933, "fiftyDayAverageChange": 0.29929972, "fiftyDayAverageChangePercent": 0.076338336, "twoHundredDayAverageChange": -1.1247253, "twoHundredDayAverageChangePercent": -0.21043652, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-12-11", "averageAnalystRating": "2.0 - Buy", "cryptoTradeable": false, "marketState": "CLOSED", "longName": "4D Molecular Therapeutics, Inc.", "exchange": "NMS", "messageBoardId": "finmb_272879653", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -3.21102, "regularMarketPrice": 4.22, "shortName": "4D Molecular Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1607697000000, "displayName": "4D Molecular Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-19"}]